PellePharm to Present at UBS Global Healthcare Conference

05.21.2018

PellePharm to Present Topical Patidegib and Skin Cancer Data

05.16.2018

Eidos Initiates Phase 2 Clinical Trial for AG10

05.03.2018

Eidos Completes $64M Series B Financing

04.05.2018

Eidos to Host Symposium on TTR Stabilization

03.20.2018

BridgeBio Licenses Late-Stage Oncology Drug Infigratinib

01.30.2018

Eidos to Present at J.P. Morgan Healthcare Conference

01.05.2018

BridgeBio Appoints CEOs to Lead Dermatology and Gene Therapy

01.04.2018

PellePharm Appoints Sanuj K. Ravindran as President

01.04.2018

FDA Grants Breakthrough Therapy Designation to PellePharm

11.20.2017

Preclinical Data Demonstrates Potential of Eidos Treatment

11.15.2017

Eidos to Present Data on its Potential Treatment for ATTR-CM

11.09.2017

Navire to Develop Therapy for Difficult-to-Treat Cancer

10.04.2017

Eidos Initiates First Clinical Study for AG10

09.28.2017

Bridgebio Expands Investor Base, Raising an Additional $135M

09.13.2017

PellePharm Shares Phase 2 Study of Topical Patidegib Results

07.31.2017

Eidos to Develop Targeted Therapy for Fatal Heart Disease

04.27.2017

Redirecting N-Acetylaspartate Metabolism in Nervous System

02.09.2017

BridgeBio Launches with a Focus on Precision Medicines

01.03.2017

PellePharm Launches with Financing from BridgeBio

12.08.2016

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn to keep up with all the latest news.

Links to an external site